1、White PaperThe Belgian Shift in Anti-Obesity Medicines How physicians,pharmacists,and patients are reshaping demandJAUME LLACER,Consultant,Business Analytics&Strategy,IQVIA Belgium KRISTIN VAN DEN DAELE,Engagement Manager,Business Analytics&Strategy,IQVIA BelgiumTable of contentsExecutive summary 1I

2、ntroduction 2Market tipping point 3Who purchases AOM?6What is the role of the pharmacist?9The persistence problem 11Economics of demand 13Phase 1 Patient background 16Phase 2 Obesity management 16Phase 3 AOM decision 16Conclusions 18Implications and considerations for pharma companies 19Appendix 20A

3、ppendix I:Anti-obesity market definition 20Appendix II:Longitudinal patient data(LRx)study 20Appendix III:Obesity survey 21Appendix IV:Obesity personas decision tree 22References 23About the authors 24 |1IQVIA Belgium initiated this white paper in response to strong indicators from its sales data:th

4、e Anti-Obesity Medication(AOM)market in Belgium is expanding rapidly,because of a high prevalence of obesity,despite the absence of reimbursement.With recent product launches and a robust pipeline of AOMs,the IQVIA team aimed to provide a comprehensive,up-to-date view of this evolving market examini

5、ng both Healthcare Professional(HCP)prescribing behaviour and patient perspectives.The findings presented here offer a multi-angle assessment of obesity care in Belgium as of 2025.Obesity is a growing public health challenge in Belgium,with 49%of the population overweight and 18%living with obesity.

6、1 Projections for 2030 suggest further increases.In response,the use of Anti-Obesity Medications(AOMs)has surged,with the number of treated patients tripling between 2022 and 2025.This growth marks a tipping point in obesity care,with General Practitioners(GPs)increasingly initiating treatment,signa